Centre for Probe Development and Commercialization

Mcmaster University

General Electric Company

Fusion Pharmaceuticals Inc.

Sunnybrook Research Institute

John Fitzmaurice Valliant

Eric Steven Burak

Ryan Wayne Simms

Tao Wu

Alla Darwish

John Richard Forbes

Karin Ann Stephenson

Meiduo Hu

Bruce Fletcher Johnson

Michael James Rishel

Randall Lee Carter

Yang Yang

Joel Adamson Drewry

Matthew David Burr Moran

Neil Grant Cockburn

Anup Sood

Mark Christopher Patrick Darey

Peter Dorff

Stuart James Mahoney

Raman Chirakal

Pierre Morel

Paul Schaffer

Oyebola O Sogbein

Julie Metcalf

Natalie Grinshtein

Naomi Matsuura

Mark Christopher Darey

The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.

Residualizing linkers and uses thereof

The present application is in the field of imaging reagents. In particular, the present application relates to labelled fluorocarbon imaging reagents, the preparation of the reagents, and their uses for imaging such as PET scanning.

Labeled fluorocarbon agents for positron emission tomography imaging

Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.

Actinium-225 and checkpoint inhibitor combination therapy

The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.

IGF-1R monoclonal antibodies and uses thereof

Pharmacokinetic enhancements of bifunctional chelates and uses thereof

An embodiment of the invention comprises method of imaging a target site comprising administrating ligand of Formula I complexed toTc wherein Rand Rare independently an alkyl or cycloalkyl; Ris and alkyl; X is CO or SO; Y is (CH2), CH, (OCHCH)(NHCHCH)and (OCHCHCH), or a combination thereof; Z is linker group capable of conjugating to a vector; and n is an integer between 0 and 10.

[object Object]

The present teachings provide methods that enable the preparation and purification of radioiodinated vectors without the need for HPLC purification, as well as novel precursors which include biotin-like substituents useful in such methods.

Biotin stannane for HPLC-free radioiodination

One aspect of the present invention relates to a method of purifying radiolabelled compounds comprising a) loading onto a fluorous polymer a radiolabelled compound precursor comprising a fluoroalkyl tin moiety; b) reacting the radiolabelled compound precursor with a radiolabel delivering compound to give a radiolabelled compound, wherein the fluoroalkyl tin moiety is replaced by a radiolabel; and c) eluting the radiolabelled compound from the fluorous polymer.

Methods for purifying radiolabelled compounds

The present invention relates to a new method for the preparation of radiopharmaceuticals based on technetium and rhenium. The method involves the reaction of a salt of the formula [M(CO)(X)], wherein M is selected from a radioisotope of rhenium, technetium and any other radioisotope that binds in a similar fashion, X is any suitable ligand and m is the formal charge for ligand X, with a nido-dicarbollide dianion of the formula [nido-(CBH)]and functional derivatives thereof. The method has been shown to be applicable to the preparation of radiopharmaceuticals at the tracer level.

Metal-carborane complexes for radioimaging and radiotherapy and methods for their preparation

Growing community of inventors

Ancaster, Canada

John Fitzmaurice Valliant